DelveInsight’s “Dravet Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Highlights
Key Companies working in Dravet Syndrome include Biocodex, GW Pharmaceuticals, Zogenix, Ovid Therapeutics, PTC Therapeutics, and many others.
Key Therapies included in the Dravet Syndrome market include Soticlestat, Larcaserin, STK-001, and many others.
Dravet Syndrome Overview
According to the National Organization for Rare Disorders (NORD), Dravet Syndrome (DS) is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.
Dravet Syndrome Foundation, states that is a rare, catastrophic, lifelong form of epilepsy that begins in the first year of life with frequent and/or prolonged seizures. Three stages usually associated with DS are febrile, worsening, and stabilization. Mutations of ion channels also have a major role in the pathogenesis of epilepsy syndromes thus, it is also referred to as “channelopathy”. Convulsive seizures triggered by a fever, typically around 5 to 8 months of age are the earliest symptoms of Dravet Syndrome.
Dravet Syndrome Epidemiology Insights
According to a study published by Wu et. al. (2015), the incidence of Dravet Syndrome in the US Population is 1:15,700, 80% of whom have a mutation in their SCN1A gene. Dravet Syndrome due to an SCN1A mutation is twice as common in the United States, as previously thought. Genetic testing needs to be considered in children with ≥2 prolonged febrile seizures by 1 year of age.
As per the study by Brunklaus et al. (2012), the incidence of mutation-positive Dravet Syndrome is at least 1:40900 in the UK population. Considering the 30% mutation-negative cases, the overall incidence of Dravet Syndrome might be as frequent as 1:28 600.
As per the study by Gil-Nagel et al. (2019), the average incidence rate among pediatric and adult patients is 1.1 cases and 0.5 cases per million inhabitants, respectively in Spain.
Click here to learn more about the Dravet Syndrome Market Landscape
The Report Covers the Dravet Syndrome Epidemiology Segmented by:
Dravet Syndrome prevalent cases
Dravet Syndrome incident cases
Dravet Syndrome treatment cases
Dravet Syndrome diagnosed cases
Dravet Syndrome Market Outlook
The Dravet Syndrome market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Dravet Syndrome market trends by analyzing the impact of current Dravet Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Dravet Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Dravet Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Dravet Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Dravet Syndrome Market
Biocodex
GW Pharmaceuticals
Zogenix
Ovid Therapeutics
PTC Therapeutics
And many others
Dravet Syndrome Therapies Covered and Analyzed in the Report
Soticlestat
Larcaserin
STK-001
And many others
Learn more about the Key Companies and Emerging Therapies in the Dravet Syndrome Market
Table of Contents
Key Insights
Dravet Syndrome Introduction
Executive Summary of Dravet Syndrome
Disease Background and Overview
Epidemiology and patient population
Dravet Syndrome Emerging Therapies
Dravet Syndrome Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Dravet Syndrome Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services